Loading organizations...
The Andy Hill Cancer Research Endowment (CARE) Fund operates as a public investment mechanism dedicated to advancing cancer research within Washington State. It constructs and manages a grant program that funnels resources into both public and private entities engaged in cancer studies. The fund's strategic approach involves funding scientific discoveries, alongside implementation and outcomes research, with the objective of improving health outcomes for the state’s population.
Established by the Washington State Legislature in 2015, the fund honors the legacy of former State Senator Andy Hill, a prominent advocate for robust cancer research initiatives. The foundational insight behind its creation was to establish a dedicated public endowment for cancer research, structured to attract and leverage significant private and other non-state matching funds, thereby maximizing its impact on scientific progress.
The fund serves a diverse range of beneficiaries, including universities, research institutions, and biotech firms conducting cancer research across Washington. Its long-term vision is to drive substantial advancements in cancer prevention, treatment, and cures, ultimately enhancing the quality of life for Washingtonians by fostering a thriving environment for life sciences innovation.
Andy Hill Cancer Research Endowment Fund has 1 tracked investment across 1 company. The latest tracked deal is $5.2M Series A Extension in KayoThera in July 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 19, 2023 | KayoThera | $5.2M Series A Extension | Thong Le | BioAdvance, National Institutes of Health, New Jersey Health Foundation, Pier 70 Ventures, WRF Capital |